Adage Capital Partners’s Ascendis Pharma ASND Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-66,500
Closed -$17.7M – 1065
2026
Q2
$17.7M Buy
+66,500
New +$15.5M 0.02% 551
2025
Q3
– Sell
-459,606
Closed -$79.3M – 886
2025
Q2
$79.3M Buy
459,606
+132,201
+40% +$21.5M 0.13% 152
2025
Q1
$51M Buy
+327,405
New +$46.8M 0.09% 222
2024
Q4
– Sell
-486,957
Closed -$72.7M – 878
2024
Q3
$72.7M Sell
486,957
-333,555
-41% -$45M 0.13% 165
2024
Q2
$112M Buy
820,512
+611,000
+292% +$83.1M 0.21% 94
2024
Q1
$31.7M Buy
209,512
+65,512
+45% +$9.35M 0.06% 339
2023
Q4
$18.1M Sell
144,000
-382,371
-73% -$38.1M 0.04% 450
2023
Q3
$49.3M Sell
526,371
-162,629
-24% -$15.2M 0.11% 200
2023
Q2
$61.5M Buy
689,000
+189,000
+38% +$16.4M 0.13% 169
2023
Q1
$53.6M Sell
500,000
-140,000
-22% -$16M 0.12% 201
2022
Q4
$78.2M Buy
640,000
+410,000
+178% +$47.6M 0.19% 131
2022
Q3
$23.8M Buy
230,000
+65,000
+39% +$6.16M 0.06% 359
2022
Q2
$15.3M Sell
165,000
-7,000
-4% -$660K 0.04% 536
2022
Q1
$20.2M Buy
172,000
+122,000
+244% +$14.1M 0.04% 447
2021
Q4
$6.73M Buy
+50,000
New +$7.44M 0.01% 784
2020
Q3
– Sell
-30,000
Closed -$4.44M – 756
2020
Q2
$4.44M Sell
30,000
-10,000
-25% -$1.37M 0.01% 637
2020
Q1
$4.5M Hold
40,000
– – 0.01% 584
2019
Q4
$5.56M Sell
40,000
-160,000
-80% -$17.8M 0.01% 600
2019
Q3
$19.3M Sell
200,000
-50,000
-20% -$5.58M 0.05% 376
2019
Q2
$28.8M Buy
250,000
+25,000
+11% +$2.99M 0.07% 300
2019
Q1
$26.5M Sell
225,000
-100,000
-31% -$8.76M 0.07% 318
2018
Q4
$20.4M Buy
325,000
+75,000
+30% +$4.71M 0.06% 321
2018
Q3
$17.7M Buy
250,000
+25,000
+11% +$1.72M 0.04% 428
2018
Q2
$15M Sell
225,000
-350,000
-61% -$23M 0.03% 474
2018
Q1
$37.6M Buy
575,000
+556,000
+2,926% +$31.2M 0.09% 274
2017
Q4
$761K Buy
+19,000
New +$691K ﹤0.01% 684

Other funds holding ASND

Adage Capital Partners's ASND Position: Q3 2026 in Review

Adage Capital Partners sold out of Ascendis Pharma (ASND) in Q3 2026, closing a stake of 66,500 shares — an estimated $17.7M sold.

Adage Capital Partners first reported a position in ASND in Q4 2017 and held it in 26 quarters. The position peaked at $112M in Q2 2024. 346 funds tracked by Wall St. Rank hold ASND as of Q3 2026.

  • Adage Capital Partners reported no remaining Ascendis Pharma position as of Q3 2026 after selling out during the quarter.
  • Adage Capital Partners sold 66,500 Ascendis Pharma shares in Q3 2026, an estimated $17.7M.
  • Adage Capital Partners first reported a position in Ascendis Pharma in Q4 2017 and held it in 26 quarters.
  • Adage Capital Partners's Ascendis Pharma position peaked at $112M in Q2 2024.
  • 346 funds tracked by Wall St. Rank held Ascendis Pharma as of Q3 2026.

Based on Adage Capital Partners's 13F filing for Q3 2026, filed 16 Nov 2026.